<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Novelion Therapeutics Inc.

    Novelion Therapeutics Inc.

    Novelion Therapeutics Inc. (“Novelion"), headquartered in Vancouver, British Col...

    Novelion Therapeutics Inc. (“Novelion"), head...

    Filing Type:    PU
    Kala Pharmaceuticals, Inc.

    Kala Pharmaceuticals, Inc.

    Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the de...

    Kala Pharmaceuticals, Inc. (Kala) is a biopharm...

    Filing Type:    PU
    Merck KGaA

    Merck KGaA

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...

    Merck KGaA, Darmstadt, Germany, a leading scien...

    Filing Type:    PU
    Otonomy, Inc.

    Otonomy, Inc.

    Otonomy is a biopharmaceutical company dedicated to the development of innovative ...

    Otonomy is a biopharmaceutical company dedicate...

    Filing Type:    PU
    Shionogi & Co. Ltd.

    Shionogi & Co. Ltd.

    Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, an...

    Shionogi & Co., Ltd. engages in the research, d...

    Filing Type:    PU
    CASI Pharmaceuticals, Inc.

    CASI Pharmaceuticals, Inc.

    CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and a...

    CASI is a U.S. NASDAQ-listed biopharmaceutical ...

    Filing Type:    PU
    Molecular Templates, Inc.

    Molecular Templates, Inc.

    Molecular Templates is focused on the discovery, development, and commercializatio...

    Molecular Templates is focused on the discovery...

    Filing Type:    PU
    Omeros Corporation

    Omeros Corporation

    Omeros is a commercial-stage biopharmaceutical company committed to discovering, d...

    Omeros is a commercial-stage biopharmaceutical ...

    Filing Type:    PU
    argenx SE

    argenx SE

    argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...

    argenx is a clinical-stage biotechnology compan...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.